AC Immune Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

AC ImmuneDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -20.2% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind rückläufig mit einer durchschnittlichen Rate von 52.3% pro Jahr.

Wichtige Informationen

-20.2%

Wachstumsrate der Gewinne

-17.0%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	-52.3%
Eigenkapitalrendite	-30.6%
Netto-Marge	-97.3%
Letzte Ertragsaktualisierung	30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

Jul 26

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Jun 15

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

Jun 15

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

May 24

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Apr 05

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

Jul 06

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Feb 03

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Jun 02

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

May 09

AC Immune reports Q1 results; outlook

Apr 28

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Feb 28

Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

Jan 24

We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

Jan 19

If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Dec 15

Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Nov 19

AC Immune EPS misses by CHF0.02, beats on revenue

Nov 13

AC Immune and Wuxi Biologics boost development of TDP-43 antibodies

Nov 09

AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 30

Aufschlüsselung der Einnahmen und Ausgaben

Wie AC Immune Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGM:ACIU Einnahmen, Ausgaben und Erträge (CHF Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten
30 Sep 24	41	-40	17
30 Jun 24	15	-61	17
31 Mar 24	15	-55	16
31 Dec 23	15	-54	15
30 Sep 23	0	-68	15
30 Jun 23	4	-67	15
31 Mar 23	4	-69	16
31 Dec 22	4	-71	16
30 Sep 22	4	-73	14
30 Jun 22	0	-76	16
31 Mar 22	0	-75	17
31 Dec 21	0	-73	18
30 Sep 21	1	-71	19
30 Jun 21	2	-74	19
31 Mar 21	3	-71	18
31 Dec 20	15	-62	19
30 Sep 20	15	-62	19
30 Jun 20	47	-25	18
31 Mar 20	48	-26	17
31 Dec 19	110	45	16
30 Sep 19	111	50	15
30 Jun 19	80	18	14
31 Mar 19	81	24	13
31 Dec 18	7	-51	12
30 Sep 18	22	-32	12
30 Jun 18	21	-27	11
31 Mar 18	20	-29	10
31 Dec 17	20	-26	10
30 Sep 17	5	-35	10
30 Jun 17	6	-36	10
31 Mar 17	25	-10	9
31 Dec 16	23	-7	8
30 Sep 16	22	-8	5
30 Jun 16	45	21	4
31 Mar 16	39	17	4
31 Dec 15	39	20	3
30 Sep 15	65	46	4
30 Jun 15	41	21	4
31 Mar 15	28	10	3
31 Dec 14	30	11	3
31 Dec 13	9	-11	3

Qualität der Erträge: ACIU ist derzeit unrentabel.

Wachsende Gewinnspanne: ACIU ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: ACIU ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 20.2% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von ACIU verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: ACIU ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (16.6%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: ACIU hat eine negative Eigenkapitalrendite (-30.63%), da es derzeit unrentabel ist.

AC Immune Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020)

Full year 2020 earnings released: CHF0.86 loss per share (vs CHF0.64 profit in FY 2019)

Third quarter 2020 earnings released: CHF0.26 loss per share

First half earnings released

Recent updates

Ac Immune Reports Positive Interim Results from Phase 2 Trial of Aci-7104.056 Active Immunotherapy in Early Parkinson’S Disease

AC Immune SA has filed a Follow-on Equity Offering in the amount of $80 million.

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business

Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being

AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up

AC Immune SA, Annual General Meeting, Jun 20, 2024

New minor risk - Profitability

Consensus revenue estimates increase by 299%

Forecast to breakeven in 2025

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Consensus revenue estimates fall by 55%

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 57%

Co-Founder notifies of intention to sell stock

New minor risk - Shareholder dilution

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

Co-Founder notifies of intention to sell stock

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

Consensus revenue estimates fall by 58%

New major risk - Revenue and earnings growth

Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

AC Immune SA Announces Executive Changes

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease

New major risk - Share price stability

AC Immune SA Announces Not Stand for Re-Election of Board of Directors

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

AC Immune SA, Annual General Meeting, Jun 23, 2023

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

Consensus forecasts updated

AC Immune’s Alzheimer’s Disease Vaccine-Candidate ACI-35.030 Selected for Further Development

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

Consensus revenue estimates increase by 75%

AC Immune SA Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome

AC Immune SA Presents Detailed Data from the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented At AAIC

AC Immune Non-GAAP EPS of -$0.23 in-line

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

AC Immune SA Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

AC Immune SA, Annual General Meeting, Jun 24, 2022

AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

AC Immune SA Announces Executive Changes

Consensus forecasts updated

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Co-Founder notifies of intention to sell stock

Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020)

Co-Founder notifies of intention to sell stock

AC Immune SA Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

Consensus forecasts updated

Co-Founder notifies of intention to sell stock

AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

AC Immune reports Q1 results; outlook

Full year 2020 earnings released: CHF0.86 loss per share (vs CHF0.64 profit in FY 2019)

Consensus forecasts updated

AC Immune SA Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine

AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

AC Immune SA, Annual General Meeting, Mar 31, 2021

AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

New 90-day high: US$8.43